Navigation Links
MIT research holds promise for Huntington's treatment

Researchers at MIT and Harvard Medical School have identified a compound that interferes with the pathogenic effects of Huntington's disease, a discovery that could lead to development of a new treatment for the disease.

There is no cure for Huntington's, a neurodegenerative disorder that now afflicts 30,000 Americans, with another 150,000 at risk. The fatal disease, which is genetically inherited, usually strikes in midlife and causes uncontrolled movements, loss of cognitive function and emotional disturbance.

"There are now some drugs that can help with the symptoms, but we can't stop the course of the disease or its onset," said Ruth Bodner, lead author on a paper appearing online the week of Mar. 6 in the Proceedings of the National Academy of Sciences (PNAS). Bodner is a postdoctoral fellow in MIT's Center for Cancer Research.

The compound developed by Bodner and others in the laboratories of MIT Professor of Biology David Housman, Harvard Medical School Assistant Professor Aleksey Kazantsev and Harvard Medical School Professor Bradley Hyman might lead to a drug that could help stop the deadly sequence of cellular events that Huntington's unleashes.

"Depending on its target, any one compound will probably block only a subset of the pathogenic effects," Bodner said.

Huntington's disease is caused by misfolded proteins, called huntingtin proteins, that aggregate and eventually form large clump-like "inclusions." The disease is characterized by degeneration in the striatum, an area associated with motor and learning functions, and the cortex. The proteins may disrupt the function of cellular structures known as proteasomes, which perform a "trash can" function for the cell -- disposing of cellular proteins that are misfolded or no longer needed, said Bodner.

Without a functional proteasome, those cellular proteins accumulate, poisoning brain cells and impairing patients' motor and cognitive function.

Until
'"/>

Source:Massachusetts Institute of Technology


Page: 1 2

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MIT research holds promise for Huntington treatment

(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... NJIT Distinguished Professor Philip R. Goode and the Big Bear ... a deformable mirror in what is called adaptive optics ... an image of a sunspot was published yesterday on the ... day: http://www.cieletespace.fr/node/5752 "This photo ...
... With children going back to school, parents are concerned that ... who dine in a school cafeteria. New research funded ... eat school lunches that are part of the federal government,s ... The same research study found, however, that children who ...
... to locate and identify a gene responsible for a fatal ... may be responsible for a similar rare, fatal disease in ... of the disease in dogs and is the first step ... Dr. Natasha Olby, associate professor of neurology, was part ...
Cached Biology News:See amazing new sun images from NJIT's Big Bear Solar Observatory 2USDA-backed study finds federal school lunches linked to childhood obesity 2USDA-backed study finds federal school lunches linked to childhood obesity 3Researchers find gene responsible for neurodegenerative disease in dogs, possibly in humans 2
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... Chicago, Illinois (PRWEB) December 22, 2014 ... representing tenants and occupiers of commercial real estate, has ... two new offices in Perth and Brisbane, Western Australia, ... board of directors. , ITRA Global / ACORPP ... and totally independent consultancy company providing property services to ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... N.J., Jan. 28 Arno Therapeutics, Inc., a,privately ... entered into,worldwide, exclusive license agreements with The Ohio ... novel, orally available,targeted therapies for cancer., Pursuant ... to several,small molecules for the treatment of cancer, ...
... Paper Provides Rationale for Continued Development of CNDO103 as ... ... Coronado Biosciences Inc. today,announced the publication of data demonstrating that the ... while,demonstrating less toxicity than Gossypol in vivo in mice., Published ...
... Jan. 28 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), ... wave of,antibody therapeutics, today announced it has completed ... to discuss the upcoming IND,submission for ARH460-16-2, its ... anti-cancer antibody targeting a novel epitope of CD44,found ...
Cached Biology Technology:Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 2Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 3Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 2Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 3Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program 2Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program 3
... Crotalus adamanteus venom Description: Phosphodiesterase ... used in studying nucleic acid ... It hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ... Phosphodiesterase I cleaves ADP-ribosylated proteins ...
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... is a recombinant Moloney murine leukemia ... Transcriptase is similar to MuLV reverse ... usage. MuLV reverse transcriptase is a ... single-stranded RNA as a template in ...
... F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite ... in rabbits, monkeys and humans. 8-iso ... non-specific lipid peroxidation. In both humans ... converted primarily to metabolites having 2 ...
Biology Products: